高最大剂量立体定向放疗改善早期非小细胞肺癌局部控制与生存
回顾性研究纳入433例接受50-60Gy/5次、最大剂量62.5-100Gy的周围型早期非小细胞肺癌患者,按计划靶区最大BED阈值200Gy分为高BED组与低BED组,倾向评分匹配后各154例。高BED组5年局部复发率、任何复发率、癌症特异性死亡率均显著低于低BED组,总生存显著更优,且未增加毒性。
核心结论
- 周围型早期非小细胞肺癌SBRT采用高最大剂量可能不仅改善局部控制,还改善任何复发、癌症特异性死亡和总生存,且未增加毒性。
研究设计与样本
- 回顾性研究纳入2005-2019年连续接受SBRT的早期非小细胞肺癌患者,处方50-60Gy/5次、最大剂量62.5-100Gy,按计划靶区内最大BED阈值200Gy分组,共433例(高BED组262例、低BED组171例),倾向评分匹配后各154例。
主要发现
- 高BED组中位随访52.3个月(范围0.8-107.2个月),低BED组中位随访121.6个月(范围3.0-162.8个月)。
关键数值与推荐
- 高BED与低BED分组阈值为计划靶区内最大BED 200Gy。
- 处方剂量范围50-60Gy/5次,最大剂量范围62.5-100Gy。
临床怎么用
- 对周围型早期非小细胞肺癌行SBRT时,可考虑在安全前提下提高计划靶区内最大BED至200Gy以上以改善局部控制及生存。
- 需进一步开展试验评估更高强度SBRT是否增加局部控制率并改善癌症特异性死亡和总生存。
局限性
- 本研究为回顾性分析,高BED组与低BED组随访时间差异较大。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We investigated whether delivery of a high biologically effective dose (BED) to primary tumors affects systemic outcomes of cancer-specific death (CSD) and overall survival (OS) rates after stereotactic body radiation therapy (SBRT) in patients with early-stage non-small cell lung cancer (ES-NSCLC). METHODS AND MATERIALS: Among consecutive ES-NSCLC patients treated with SBRT between 2005 and 2019, we retrospectively identified patients who received a prescription of 50 to 60 Gy in 5 fractions with maximum doses of 62.5 to 100 Gy. Patients were categorized by maximum BED within the planning target volume with a threshold dose of 200 Gy. Outcomes were analyzed in all and matched patients. RESULTS: Overall, 433 patients were eligible, and 262 and 171 patients were categorized into HighBED and LowBED groups, respectively. After propensity score matching, pairs of 154 patients were selected. Median follow-up times for the HighBED and LowBED groups were 52.3 months (range, 0.8-107.2 months) and 121.6 months (range, 3.0-162.8 months), respectively. The local recurrence rate in the HighBED group was significantly lower than that in the LowBED group (5-year rate, 1.3% and 7.2%; hazard ratio [HR], 0.15; 95% confidence interval [CI], 0.03-0.65; P = .011). Rates of any recurrence and CSD in the HighBED group were significantly lower (5-year any recurrence: 18.1% and 32.1%; HR, 0.52; 95% CI, 0.33-0.83; P = .0058; 5-year CSD: 9.5% and 21.8%; HR, 0.38; 95% CI, 0.20-0.70; P = .002), and OS in the HighBED group was significantly better compared with the LowBED group (5-year rate: 61.7% and 51.8%; HR, 0.71; 95% CI, 0.50-1.00; P = .047). CONCLUSION: In patients with peripheral ES-NSCLC, SBRT with a high maximum dose may improve not only local control, but also any recurrence, CSD, and OS rates without increased toxicity. Further trials designed to evaluate whether higher intensity SBRT increases local control rates and contributes to improved CSD and OS outcomes are anticipated.
引用
- Tateishi Y, Takeda A, Horita N, et al. Stereotactic Body Radiation Therapy With a High Maximum Dose Improves Local Control, Cancer-Specific Death, and Overall Survival in Peripheral Early-Stage Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2021. PMID: 33891980. doi:10.1016/j.ijrobp.2021.04.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。